Here at Amnion Life, we are at a critical point in our mission to reduce preterm birth complications. The team has made great strides in advancing the development of the AmnioBed™ , our innovative neonatal incubator system that is designed to mimic the amniotic environment of a mother’s womb.
Over the past year, we built a functioning prototype, won the Gold Medal at the Accelerator Showcase hosted by the UCSF-Stanford Pediatric Device Consortium, and were accepted into the Stanford Biodesign Accelerator program. None of this would have been possible without our investors who have joined our fight to reduce infant mortality.
There is important work ahead of us, and we hope to have our investors’ support once again.
Our goal is simple: to raise $2.5 million to complete preclinical testing on Amniobed, go through clinical trials and file with the FDA. The minimum investment on RedCrow starts at $5,000. As a sign of our gratitude, for each investor who contributes to our campaign in this offering, a plaque in their name will be dedicated to an AmnioBed.
I ask you to take a few minutes to think about your friends and family members who may have a personal experience with a preterm infant. If you know someone who may be interested in supporting our pursuit of safe and effective technologies to help vulnerable preterm babies, please consider forwarding this email to them.
Our RedCrow campaign ends on Christmas Day, December 25th, 2019. Only with the help of our investors will we be able to deliver the AmnioBed to preterm infants in need. We remain focused, passionate, and committed to protecting the lives of preterm babies. I hope you or your loved ones can join us as we embark on this exciting next phase of development.
Dr. Amir Fassihi